Keywords
asymptomatic, pre-symptomatic, elders, COVID-19, risk factors, dementia, geriatric institutions, long-term facilities
-
Views
-
Downloads
How to cite this article
Esteban I, Bergero G, Alves C et al. Asymptomatic COVID-19 in the elderly: dementia and viral clearance as risk factors for disease progression. [version 1; peer review: 1 approved, 1 approved with reservations]. Gates Open Res 2021, 5:143 (https://doi.org/10.12688/gatesopenres.13357.1)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Export Citation
Sciwheel
EndNote
Ref. Manager
Bibtex
ProCite
Sente
▬
✚
Research Article
Asymptomatic COVID-19 in the elderly: dementia and viral clearance as risk factors for disease progression.
[version 1; peer review: 1 approved, 1 approved with reservations]
PUBLISHED 27 Aug 2021
OPEN PEER REVIEW
REVIEWER STATUS
Abstract
Corresponding authors:
Ignacio Esteban, Fernando P. Polack
Competing interests:
Declaration of interests: I.E., G.B., C.A., M.B., V.Z., C.J.W., M.T.C., D.W., R.L., and G.P.M. declare no conflict of interest. FPP reports grants and non-financial support from Novavax; personal fees from Medimmune, grants and personal fees from Janssen, personal fees from Sanofi, personal fees from Bavarian Nordic, personal fees from Pfizer, personal fees from Merck, personal fees from ArkBio, personal fees from VirBio, personal fees from Regeneron, personal fees from Daiichi Sankyo, all outside the submitted work.
Grant information:
This work was supported by the Bill & Melinda Gates Foundation [INV-017995] to FPP.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Copyright:
© 2021 Esteban I et al.
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
How to cite: Esteban I, Bergero G, Alves C et al. Asymptomatic COVID-19 in the elderly: dementia and viral clearance as risk factors for disease progression. [version 1; peer review: 1 approved, 1 approved with reservations]. Gates Open Res 2021, 5:143 (https://doi.org/10.12688/gatesopenres.13357.1)
First published: 27 Aug 2021, 5:143 (https://doi.org/10.12688/gatesopenres.13357.1)
Latest published: 04 Apr 2022, 5:143 (https://doi.org/10.12688/gatesopenres.13357.2)
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
There is a newer version
of this article available.
of this article available.
Introduction
Coronavirus disease 2019 (COVID-19) is particularly severe in the elderly1. SARS-CoV-2 infected individuals ≥60 years of age have the highest hospitalization rates and represent >80% fatalities1–3. Within this population, those who reside in long-term facilities may represent >50% of the total COVID-19 related deaths per country4–6.
However, most infected seniors remain asymptomatic and never progress to experience severe disease. While in symptomatic COVID-19 elders, the predisposing risk factors for severe disease are already well described2,3,7, among those without symptoms, the rate of pre-symptomatic illness is unclear, and potential predictors of progression for symptom development are unknown.
Our objective was to delineate the natural evolution of asymptomatic SARS-CoV-2 infection and identify determinants of progression to symptomatic illness. For this purpose, we established a prospective cohort of asymptomatic, SARS-CoV-2 infected individuals ≥60 years of age in geriatric institutions and investigated the role of baseline comorbidities, viral load on presentation, viral clearance, and antibody production in disease progression.
Methods
Study population
Our group established a medical surveillance team monitoring 63 geriatric institutions in Buenos Aires city and state between June and July 2020. When an index COVID-19 case emerged in one of these residencies, we tested all other consenting, eligible asymptomatic elders ≥60 years old for SARS-CoV-2. Participating seniors were asymptomatic individuals ≥75 years of age, or between 60–74 years with ≥1 comorbidity (hypertension, dementia, diabetes, obesity, chronic renal failure, and/or chronic obstructive pulmonary disease [COPD]).
Institutional review board approval was obtained and all patients or a responsible first-degree family member signed informed consent for their participation in the protocol (Centro de Estudios Infectológicos SA CEIC, Ethics Approval Number 1146).
Clinical monitoring
SARS-CoV-2 infected, asymptomatic elders were followed daily for 28 days by a medical team using pre-designed questionnaires. Symptoms of COVID-19 included fever (axillary temperature >37.5°C), chills, cough, tachypnea (respiratory rate >20 per minute), physician-diagnosed difficulty breathing, hypoxemia (O2 sat<93% when breathing room air), myalgia, anorexia, sore throat, dysgeusia, anosmia, diarrhea, vomiting, and rhinorrhea. Disease was diagnosed when any of these manifestations occurred within 14 days of SARS-CoV-2 detection (95% of symptomatic patients) or between 15 and 28 days of persistently positive real-time reverse transcriptase polymerase chain reaction (RT-PCR) results with no other clinical possible explanation. COVID-19 severe disease was defined as oxygen requirement due to hypoxemia. SARS-CoV-2 load at enrollment, shedding on day 15, and antibody responses at the end of study participation were also studied.
SARS-CoV-2 and antibody testing
SARS-CoV-2 was assayed in nasopharyngeal and oropharyngeal swabs following Center for Disease Control guidelines at enrollment and day 15 of diagnosis8. Samples were stored in 2 ml of normal saline and tested in duplicate by RT-PCR for SARS-CoV-2 (Atila iAMP® COVID-19).
Antibodies were assayed in 10μl of blood using a validated rapid antibody test (monoclonal immunoglobulin M (IgM) and immunoglobulin G (IgG) against SARS-CoV-2 nucleocapsid protein, SD Biosensor®, Korea) 28 days after enrollment because the test’s sensitivity is reported to be higher at 4–5 weeks9,10. The assay was performed according to the manufacturer´s protocol11.
Statistical analysis
Baseline comorbidities were reported using descriptive statistics. Differences between asymptomatic and pre-symptomatic participants were compared using the Student t-test and Chi-squared test, where appropriate. Variables with a p-value <=0.2 were defined as candidates for multivariable evaluation. A p<0.05 was considered statistically significant. Progression to symptomatic illness was assessed using the Kaplan-Meier method, with any COVID-19 related symptom as outcome. Stata/SE 13 package for IBM-PC (Stata Corp) was used for analysis and R Core Team (2019) for Figures.
Results
Study Population and clinical evolution
Thirteen of 63 (20%) senior homes presented a positive, symptomatic index case during the study period. In these residencies, we swabbed 258 asymptomatic individuals between June 8 and July 3, 2020. 113 asymptomatic SARS-CoV-2-infected elderly participated in the study. Of these, 100/113 were ≥75 years of age, and 13/113 were between 60–74 years with ≥1 comorbidity (Table 1).
Table 1. Determinants of pre-symptomatic COVID-19.
| Asymptomatic (N=75) | Pre-symptomatic (N=38) | OR (CI 95%) | p-value | |
|---|---|---|---|---|
| Clinical and laboratory | ||||
| Median age (IQR) - yr | 87.7 (11.57) | 86.6 (13.7) | 0.99 (0.99-1.00) | 0.277* |
| Male, no. (%) | 14 (19) | 6 (16) | 0·78 (0.27-2.22) | 0.64** |
| Smoking history, no. (%) | 18 (25) | 12 (33) | 1.47 (0.61-3.53) | 0.385** |
| Dementia, no. (%) | 28 (39) | 23 (61) | 2.41 (1.08-5.39) | 0.03** |
| Hypertension, no. (%) | 32 (43) | 15 (39) | 0.82 (0.37-1.81) | 0.624** |
| Diabetes, no. (%) | 12 (16) | 4 (10) | 0.59 (0.18-1.97) | 0.388** |
| Cardiovascular disease, no. (%) | 15 (20) | 8 (20) | 1.02 (0.39-2.66) | 0.976** |
| Obesity, no. (%) | 4 (5) | 4 (10) | 2 (0.47-8.48) | 0.339** |
| Cancer, no. (%) | 4 (5) | 3 (8) | 1.46 (0.31-6.87) | 0.632** |
| Chronic liver disease, no. (%) | 1 (1) | 1 (3) | 1.92 (0.12-31.57) | 0.642** |
| End-stage renal disease, no. (%) | - | 2 (5) | - | - |
| Asthma, no. (%) | - | 2 (5) | - | - |
| Chronic obstructive pulmonary disease, no. (%) | - | 3 (8) | - | - |
Participants' median age was 87 years (IQR 11.85). 93/113 (82%) were females, 98 (87%) had ≥1 comorbidity (Table 1). After 28 days of follow-up, 74 (65%) elders remained asymptomatic. In 39 (35%) pre-symptomatic patients, the median time to onset of symptoms was 3 days (IQR 6) (Figure 1). The most frequent presenting symptoms were difficulty breathing (39%), cough (37%), fever (29%), and tachypnea (16%). 21/39 (54%) pre-symptomatic patients developed hypoxemia [21/113 (19%) in the population], a presenting sign in 11/21 (52%). Median time to oxygen supplementation was 4 days (IQR 6); median duration of O2 supplementation in survivors, 4 days (IQR 5). Ten pre-symptomatic patients died (median day 13.5, IQR 12).
Figure 1. Symptom development in patients who were asymptomatic at time of COVID-19 diagnosis.
Risk factors for disease progression
None of the baseline conditions classically related to disease severity was associated with symptomatic illness (Table 1). Dementia was the only clinical risk factor associated with disease (OR 2.41 (95% CI =1.08, 5.39), p=0.03; Table 1) when compared to the asymptomatic patients. These results, with dementia as a potential predictor for the development of symptoms in our population, remained stable in a univariate logistic regression (dementia, p=0.032).
Analyzing potential predictors for COVID-19 severe disease in a multivariable logistic regression model, including variables with a p-value <=0.2 in univariate analysis (cancer history and diabetes), dementia persisted as a risk factor associated with the outcome (OR 3.02 (95% CI =1.08, 8.45), p=0.035) (Table 2). Furthermore, when assessing the cumulative probability of developing COVID-19 symptoms stratified by dementia diagnosis, it showed a statistically significant different trend in both groups (log-rank p=0.027) (Figure 2).
Table 2. Determinants of COVID-19 severe disease.
Figure 2. Symptom development in patients who were asymptomatic at time of COVID-19 diagnosis.
SARS-CoV-2 viral load and RT-PCR retesting
RT-PCR mean cycle threshold showed no differences among groups at the time of enrollment (p=0.391), with a mean of 14.65 (SD 10.13) in the asymptomatic group and a mean of 12.79 (SD 6.08) in the pre-symptomatic patients (Figure 3).
Figure 3. SARS-CoV-2 cycle threshold value in pre-symptomatic and asymptomatic patients.
When performing a second RT-PCR testing on day 15 (IQR 1), SARS-CoV-2 was detectable in 30% (14/46) of the asymptomatic subjects, while still present in 61% (17/28) of the pre-symptomatic patients (p=0.012).
Antibody seropositivity against SARS-CoV-2
All patients were invited to be tested for IgM and IgG against SARS-CoV-2 nucleocapsid protein four weeks after diagnosis. Seventy-six % (77/102) of those alive on day 28th of follow-up were assayed with a median day at testing of 28 (IQR 3).
No differences were observed in the rates of antibody seropositivity between asymptomatic and pre-symptomatic patients respectively (IgM+: 53% (31/59) vs 56% (10/18), p=0.823) (IgG+: 83% (49/59) vs 83% (15/18), p=0.978).
Discussion
Early recognition of asymptomatic infected patients and defining the determinants of progression from asymptomatic to symptomatic illness in the elderly are critical to examine potential disease-sparing interventions. However, since asymptomatic patients usually do not seek medical assistance or COVID-19 testing, this represents a great challenge.
In our cohort, 2/3 aged study participants remained asymptomatic, only 1/5 developed an oxygen requirement and 9% of all patients died due to COVID-19. Asymptomatic SARS-CoV-2 infected patients play a paramount role in the pandemic, both as sources of viral spreading and as at-risk subjects for hospitalization. Interestingly, few studies examined them in detail12. On the Diamond Princess cruise ship, 88% of asymptomatic and relatively younger patients (median=59.5 years) did not progress to disease13 while, in skilled nursing facilities in the U.S. and in line with our observations, 68% failed to develop illness14. Our case-fatality ratio in symptomatic patients (26%, 10/39), is considerably higher than the one described in Argentina and worldwide15. This emphasizes the relevance of the population under study (residents of long-term facilities), given their high susceptibility for COVID-19 severe disease4–6.
Dementia was the sole baseline difference potentially predicting progression to symptomatic disease in our study. Our findings suggest that cognitive impairment plays a key role in disease inception and disease progression in the elderly. Other comorbidities associated with progression from mild to severe symptoms2,16 did not affect the odds of experiencing pre-symptomatic illness in this population. Furthermore, dementia successfully predicted those requiring oxygen. Cognitive impairment has been previously identified in Britain as a risk factor for hospitalization in older patients (OR 3.5 (95% CI =1.93, 6.34))17. However, our study is the first to prospectively identify dementia as a risk factor for pre-symptomatic illness. There are different reasons behind the elevated mortality seen in long-term facilities worldwide and in our study, that may also explain the role of dementia and cognitive impairment in COVID-19 disease progression. To begin with, residents in geriatric institutions are in close contact with numerous healthcare workers with a consequent increased risk for contracting SARS-CoV-2 infection6. In addition, patients with cognitive impairment may present difficulties in carrying out isolation and the physical distancing needed. Furthermore, patients with dementia were described to present particularly higher blood levels of urea, white blood cell count, and an association with neurological consequences of COVID-196,18.
No difference in viral load in respiratory secretions was evident at diagnosis between groups, in line with previous reports19–21. But two weeks after enrollment, the pre-symptomatic group doubled the asymptomatic subjects in the persistence of SARS-CoV-2 detection in respiratory secretions. This longer viral shedding associated with evolution to symptomatic disease, suggests that control of viral replication may influence symptom inception. In line with our findings, infectivity may be weaker in asymptomatic elders than in those fully developing symptoms22. A recent study showed similar results in PCR retesting in SARS-CoV-2 asymptomatic and symptomatic patients, and interestingly, this could be evidenced during the first week after diagnosis23.
Antibody diagnostics tests are critical for detecting asymptomatic patients24. IgM antibodies peak 4 for days after onset of symptoms, declining to become undetectable after 4 weeks. Whereas IgG reaches detectable levels at day 7 and remains highly elevated until 8 months of diagnosis even in asymptomatic patients25–27. Interestingly, Grossberg et al. showed that symptomatic individuals experience a different immune response than asymptomatic SARS-CoV infected patients, revealed by higher levels of IgG against spike 1 and 2 glycoprotein, receptor-binding domain (RBD), and nucleoprotein. While asymptomatic patients may present a more robust IgM response28.
Nevertheless, IgM and IgG responses were similar with and without symptoms in our cohort, findings aligned with their preventive role in early stages after or even before infection but their lesser influence once disease course has been established29.
Our study has limitations. First of all, older adults, and in particular those with cognitive impairment may present greater difficulties in referring their symptoms. However, all patients were under strictly daily control by nurses and the institution's medical team that accurately reported all symptoms and signs presented. In addition, while no difference was seen among groups in the IgM and IgG levels against SARS-CoV-2 nucleocapsid protein, a more complex analysis of the immune response including neutralizing antibodies, and antibodies titers against spike glycoproteins and RBD, may elucidate differences between groups.
In summary, we present a cohort of SARS-CoV-2 infected elders from vulnerable communities in Argentina, where 2/3 of them remained asymptomatic after 28 days of follow-up with high mortality among those developing symptoms. Dementia and persistent SARS-CoV-2 shedding were associated with progression from asymptomatic to symptomatic infection. Evidently, COVID-19 risk control and prevention are imperative in this high-risk population. These observations may alter our thinking of SARS-CoV-2 asymptomatic infection in the elderly, and if confirmed in other studies, require us to include patients with dementia as candidates for prevention strategies.
Data availability
Figshare. “Asymptomatic COVID-19 in the elderly: dementia and viral clearance as risk factors for disease progression”. SAS Dataset. DOI: https://doi.org/10.6084/m9.figshare.15050217.v130
Figshare. “Asymptomatic COVID-19 in the elderly: dementia and viral clearance as risk factors for disease progression”. Stata dataset. DOI: https://doi.org/10.6084/m9.figshare.15050223.v131
Figshare. “Asymptomatic COVID-19 in the elderly: dementia and viral clearance as risk factors for disease progression”. Stata Dofile. DOI: https://doi.org/10.6084/m9.figshare.15050220.v132
Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).
Download
Export To
metrics
| Views | Downloads | |
|---|---|---|
| Gates Open Research | - | - |
|
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Citations
CITE
how to cite this article
Esteban I, Bergero G, Alves C et al. Asymptomatic COVID-19 in the elderly: dementia and viral clearance as risk factors for disease progression. [version 1; peer review: 1 approved, 1 approved with reservations] Gates Open Res 2021, 5:143 (https://doi.org/10.12688/gatesopenres.13357.1)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.
Open Peer Review
Current Reviewer Status:
Key to Reviewer Statuses
VIEW
HIDE
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations
A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 1
VERSION 1
PUBLISHED 27 Aug 2021
Views
15
How to cite this report:
Wiens KE. Reviewer Report For: Asymptomatic COVID-19 in the elderly: dementia and viral clearance as risk factors for disease progression. [version 1; peer review: 1 approved, 1 approved with reservations]. Gates Open Res 2021, 5:143 (https://doi.org/10.21956/gatesopenres.14601.r31683)
The direct URL for this report is:
https://gatesopenresearch.org/articles/5-143/v1#referee-response-31683
https://gatesopenresearch.org/articles/5-143/v1#referee-response-31683
NOTE: it is important to ensure the information in square brackets after the title is included in this citation.
Reviewer Report 16 Feb 2022
Approved with Reservations
VIEWS 15
In this paper, Esteban et al. conduct a prospective study of 113 SARS-CoV-2-infected elderly adults in 13 senior homes in Buenos Aires during June-July 2020. They follow the study participants over 28 days, monitoring symptoms, viral load, and IgM/IgG responses
... Continue reading
CITE
HOW TO CITE THIS REPORT
Wiens KE. Reviewer Report For: Asymptomatic COVID-19 in the elderly: dementia and viral clearance as risk factors for disease progression. [version 1; peer review: 1 approved, 1 approved with reservations]. Gates Open Res 2021, 5:143 (https://doi.org/10.21956/gatesopenres.14601.r31683)
The direct URL for this report is:
https://gatesopenresearch.org/articles/5-143/v1#referee-response-31683
https://gatesopenresearch.org/articles/5-143/v1#referee-response-31683
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
-
Author Response 04 Apr 2022Ignacio Esteban, INFANT Foundation, Buenos Aires, Argentina04 Apr 2022Author ResponseResponse to Reviewer 2:
In this paper, Esteban et al. conduct a prospective study of 113 SARS-CoV-2-infected elderly adults in 13 senior homes in Buenos Aires during June-July 2020. They follow ... Continue reading
COMMENTS ON THIS REPORT
-
Author Response 04 Apr 2022Ignacio Esteban, INFANT Foundation, Buenos Aires, Argentina04 Apr 2022Author ResponseResponse to Reviewer 2:
In this paper, Esteban et al. conduct a prospective study of 113 SARS-CoV-2-infected elderly adults in 13 senior homes in Buenos Aires during June-July 2020. They follow ... Continue reading
Views
18
How to cite this report:
Dobaño C. Reviewer Report For: Asymptomatic COVID-19 in the elderly: dementia and viral clearance as risk factors for disease progression. [version 1; peer review: 1 approved, 1 approved with reservations]. Gates Open Res 2021, 5:143 (https://doi.org/10.21956/gatesopenres.14601.r31188)
The direct URL for this report is:
https://gatesopenresearch.org/articles/5-143/v1#referee-response-31188
https://gatesopenresearch.org/articles/5-143/v1#referee-response-31188
NOTE: it is important to ensure the information in square brackets after the title is included in this citation.
Reviewer Report 06 Oct 2021
Approved
VIEWS 18
The article by Esteban et al. presents a longitudinal study in long-term geriatric facilities to evaluate the proportion of individuals with asymptomatic vs symptomatic SARS-CoV-2 infection and the risk factors for negative disease progression and mortality in Argentina. Data from
... Continue reading
CITE
HOW TO CITE THIS REPORT
Dobaño C. Reviewer Report For: Asymptomatic COVID-19 in the elderly: dementia and viral clearance as risk factors for disease progression. [version 1; peer review: 1 approved, 1 approved with reservations]. Gates Open Res 2021, 5:143 (https://doi.org/10.21956/gatesopenres.14601.r31188)
The direct URL for this report is:
https://gatesopenresearch.org/articles/5-143/v1#referee-response-31188
https://gatesopenresearch.org/articles/5-143/v1#referee-response-31188
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations -
A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Competing Interests Policy
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Examples of 'Non-Financial Competing Interests'
- Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.
- You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.
- You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).
- You work at the same institute as any of the authors.
- You hope/expect to benefit (e.g. favour or employment) as a result of your submission.
- You are an Editor for the journal in which the article is published.
Examples of 'Financial Competing Interests'
- You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.
- You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.
- You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.
Stay Updated
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Register with Gates Open Research
Already registered? Sign in
Comments on this article Comments (0)